SUPERNUS PHARMACEUTICALS, INC.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Large accelerated filer
State of Incorporation
DE
Business Address
9715 KEY WEST AVENUE, ROCKVILLE, MD, 20850
Mailing Address
9715 KEY WEST AVENUE, ROCKVILLE, MD, 20850
Phone
301-838-2500
Fiscal Year End
1231
EIN
000000000
Financial Overview
FY2025
$1.45B
Total Assets
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | March 27, 2026 | View on SEC |
| 4 Insider stock transaction report | March 18, 2026 | View on SEC |
| 4 Insider stock transaction report | March 16, 2026 | View on SEC |
| 4 Insider stock transaction report | March 16, 2026 | View on SEC |
| 3 Initial insider ownership report | March 10, 2026 | View on SEC |
| 4 Insider stock transaction report | March 10, 2026 | View on SEC |
| 4 Insider stock transaction report | March 10, 2026 | View on SEC |
| 4 Insider stock transaction report | March 10, 2026 | View on SEC |
| 4 Insider stock transaction report | March 10, 2026 | View on SEC |
| 4 Insider stock transaction report | March 9, 2026 | View on SEC |
Annual Reports
10-K
March 2, 2026
- Continued revenue growth in 2024, driven by strong performance of key products Qelbree and GOCOVRI.
- Strategic acquisition of ONAPGO in late 2024, positioning the company for future growth with planned commercial launches in 2025.
Insider Trading
STRONG SELL
7 insiders
20 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.